[Limited Access] HTML Full Text-PDF
American Journal of BioMedicine Volume 2, Issue 7, pages 870-886, July 2014
Johannes Granter; Michael B. Calvin; John G. Westover; Ye Wu; Ting Lee; Li Kim; Philip Frugier
Abstract
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that has protean manifestations and follows a relapsing and remitting course. More than 90% of cases of SLE occur in women, frequently starting at childbearing age. The pattern of tissue injury in SLE is primarily related to the formation of the immune complexes deposits that can induce the inflammatory response by activation of adhesion molecules on endothelium, resulting in the recruitment of pro inflammatory leukocytes. The goal of this study was to investigate the expression of orphan receptor GPR15/BOB in the lesion/ peripheral blood of SLE patients and non-SLE patients. Messenger RNA expression was examined by reverse-transcription polymerase chain reaction (RT-PCR) and GPR15/BOB protein by immunofluorescence. Cytokines were analyzed from blood serum using enzyme linked immunoassay (ELISA) for IL-6 and INF-α. Further; GPR15/BOB expression on peripheral blood leukocytes was analysed by flow cytometry. GPR15/BOB (P=0.002) expression levels were significantly increased in lupus patients compared to age-matched controls. African American women with lupus had a 2-fold increase in GPR15/BOB expression level when compared to their healthy controls or European American lupus patients. Serum levels revealed significant increases in expression of IL-6, IFN-γ and TNF-α in lupus patients with expression of GPR15/BOB compared to non-expression of GPR15/BOB -lupus patients. This study shows expression of GPR15/BOB is up-regulation in SLE patients and provides an opportunity for targeting with antagonist as a novel therapy for SLE.
Keywords: SLE; GPR15/BOB; African American women; Pro-inflammatory cytokines; Immune complexes
References
1. Vasudevan A, Krishnamurthy AN: Changing worldwide epidemiology of systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36(1):1-13. [PubMed]
2. , , . Systemic sclerosis and scleroderma variants: clinical aspects. In: KoopmanWJ, MorelandLW, editors. Arthritis and Allied Conditions. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1633–80.
3. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45: 694–702. [PubMed]
4. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG, Gilkeson GS. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41(10):1714-24. [PubMed]
5. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN: Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010,19(5): 557-574. [PubMed]
6. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58: 1465–74. [Abstract/Full-Text]
7. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29: 150–64. [PubMed]
8. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550–5. [PubMed]
9. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of Systemic Lupus Activity Measure-Revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10: 405–9. [PubMed]
10. Denton CP, Black CM. Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol 2004; 18: 271–90. [PubMed]
11. Cartwright A, Schmutz C, Askari A, Kuiper JH, Middleton J. Orphan receptor GPR15/BOB is up-regulated in rheumatoid arthritis. Cytokine 2014; 67(2): 53-9. [PubMed]
12. Maresca M, Mahfoud R, Garmy N, Kotler DP, Fantini J, Clayton F. The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line. J Biomed Sci 2003;10(1):156-66. [PubMed]
13. Clayton F, Kotler DP, Kuwada SK, Morgan T, Stepan C, Kuang J, Le J, Fantini J. Gp120-induced Bob/GPR15 activation: a possible cause of human immunodeficiency virus enteropathy. Am J Pathol. 2001;159(5):1933-9. [PubMed]
14. Pöhlmann S, Krumbiegel M, Kirchhoff F. Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1. J Gen Virol 1999;80(Pt 5):1241-51. [PubMed]
15. Galligan CL, Matsuyama W, Matsukawa A, Mizuta H, Hodge DR, Howard OM, Yoshimura T. Up-regulated expression and activation of the orphan chemokine receptor, CCRL2, in rheumatoid arthritis. Arthritis Rheum. 2004;50(6):1806-14. [PubMed]
16. Gupta SK, Pillarisetti K. Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant. J Immunol 1999; 163: 2368–72. [PubMed]
17. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 1994; 91: 2752–6. [PubMed]
18. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537–49. [PubMed]
19. Ruth JH, Shahrara S, Park CC, Morel JC, Kumar P, Qin S, et al. Role of macrophage inflammatory protein-3α and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003; 83: 579–88. [PubMed]
20. Volin MV, Shah MR, Tokuhira M, Haines GK, Woods JM, Koch AE. RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol Immunopathol 1998; 89: 44–53. [PubMed]
21. Ahuja S, Shetty A, Tiffany H, Murphy P. Comparison of the genomic organization and promoter function for human interleukin-8 receptors A and B. J Biol Chem 1994; 269: 26381–9. [PubMed]
22. Pan Q, Li Y, Ye L, Deng Z, Li L, Feng Y, Liu W, Liu H. Geographical distribution, a risk factor for the incidence of lupus nephritis in China. BMC Nephrol 2014;15:67. [PubMed]
23. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004; (1): CD002922. [PubMed]
24. Nossent JC: Systemic lupus erythematosus on the Caribbean island of Curaçao: an epidemiological investigation. Ann Rheum Dis 1992; 51(11):1197-1201. [PubMed]
25. 23. Boldron J; Caltabiano S; Debono SD; Thompson R; Scammells M; Westover R; Wu Y; Frugier P. Adhesion molecule expression trigger immune-mediated pathology in lupus-nephritis. American Journal of BioMedicine 2013;1(2): 49-57. [Abstract/Full-Text]
26. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA: Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002; 112(9): 726-729. [PubMed]
27. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, Chaussabel D. et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010; 62, 589–598. [PubMed]
28. Patel M, Clarke AM, Bruce IN, Symmons DP: The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum 2006; 54(9): 2963-2969. [PubMed]
29. Houssiau FA: Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15(10): 2694-2704. [PubMed]
